Galectin Therapeutics Inc. thinks subgroup analysis of its failed Phase IIb study in non-alcoholic steatohepatitis (NASH) highlights a way forward for its complex carbohydrate drug GR-MD-02, but investors don't seem to agree.
The Norcross, Ga., biotech reported Dec. 5 that GR-MD-02, targeting the galectin-3 protein which plays a role in fatty liver...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)